Privacy Policy

FHL Therapeutics Website Privacy Policy


Forest Hills Partners (“us”, “we”, or “our”) operates https://fhltherapeutics.com/ (the “Website”).
We are committed to ensuring that your privacy is protected and this page informs you of our policies regarding the collection, use and disclosure of Personal Information we receive from users of the Website. If you are asked to provide information when using the Website, it will only be used in the ways described in this privacy policy.
By using the Site, you agree to the collection and use of information in accordance with this policy.



Information Collection


While using the Website, we may ask you to provide us with certain personally identifiable information. Personally identifiable information may include, but is not limited to your name, address, email address, contact number (“Personal Information”).
By using the Site, you agree to the collection and use of information in accordance with this policy.



Use of Information


We use this information in order to provide products and services, to enable certain functions on the Website and to understand your needs and provide you with a better service, and in particular for the following reasons:


• To complete order/s purchased via the Website, and to process your payments

• To improve our products and services we provide

• To customize the Website for you. Internal record keeping, and administrative purposes

• To contact you in response to specific enquiry



Cookies


Cookies are files with small amount of data, which may include an anonymous unique identifier. Cookies are sent to your browser from a web site and stored on your computer’s hard drive. Like many sites, we use “cookies” to collect information. You can instruct your browser to refuse all cookies or to indicate when a cookie is being sent. However, if you do not accept cookies, you may not be able to use some portions of our Site.



Security


The security of your Personal Information is important to us, but remember the internet is not a secure medium. However, we take reasonable technical and organizational precautions to prevent the loss, misuse or alteration of your personal information.



Changes to This Privacy Policy


This Privacy Policy is effective as of December 1, 2023 and will remain in effect except with respect to any changes in its provisions in the future, which will be in effect immediately after being posted on this page. We reserve the right to make changes to this privacy policy from time to time and you should check this Privacy Policy periodically. Your continued use of the Website after we post any modifications to the Privacy Policy on this page will constitute your acknowledgment of the modifications and your consent to abide and be bound by the modified Privacy Policy.



Contact Us


If you have any questions about this Privacy Policy, please contact us at +852 2155 0487 or email us at info@foresthillslab.com.

Terms & Conditions

FHL Therapeutics Website Privacy Policy


Forest Hills Partners (“FHP”) owns and operates this website (https://fhltherapeutics.com/). (This document governs your relationship with our website. These Terms and Conditions (the “Terms”) contained herein on this webpage, shall govern your use of the website, including all pages within this website (the “Website”). The Terms apply in full force and effect to your use of the Website and by accessing the Website, you agree to be bound by the Terms contained herein in full. You must not use the Website, if you disagree with any part of the Terms.



Age Restriction


You must be at least 18 years of age to use the Website; by using the Website or agreeing to the Terms, you warrant and represent to us that you are at least 18 years of age.



Intellectual Property Rights


The intellectual property rights in all software and content (including photographic images) made available to you on or through the Website remains the property of FHP or its licensors and are protected by copyright laws and treaties around the world. All such rights are reserved by FHP and its licensors. You may store, print and display the content supplied solely for your own personal use. You are not permitted to publish, manipulate, distribute or otherwise reproduce, in any format, any of the content or copies of the content supplied to you or which appears on the Website nor may you use any such content in connection with any business or commercial enterprise.



Coockies


Cookies are files with small amount of data, which may include an anonymous unique identifier. Cookies are sent to your browser from a web site and stored on your computer’s hard drive. Like many sites, we use “cookies” to collect information. You can instruct your browser to refuse all cookies or to indicate when a cookie is being sent. However, if you do not accept cookies, you may not be able to use some portions of our Site.



Prohibitions


You are expressly and emphatically restricted from all of the following: publishing any the Website material in any media; selling, sublicensing and/or otherwise commercializing any the Website material transmit or distribute a virus, trojan, worm, logic bomb or any other material which is malicious, technologically harmful, in breach of confidence or in any way offensive or obscene; using the Website in any way that impacts user access to the Website; engaging in any data mining, data harvesting, data extracting or any other similar activity in relation to the Website, or while using the Website; send any unsolicited advertising or promotional material, commonly referred to as “spam”;
Breaching this provision would constitute a criminal offense and FHP will report any such breach to the relevant law enforcement authorities and disclose your identity to them.
We will not be liable for any loss or damage caused by a distributed denial-of-service attack, viruses or other technologically harmful material that may infect your computer equipment, computer programs, data or other proprietary material due to your use of the Website or to your downloading of any material posted on it, or on any the website linked to it



No Warranties


The Website is provided “as is,” with all faults, and FHP makes no express or implied representations or warranties, of any kind related to the Website or the materials contained on the Website. Additionally, nothing contained on the Website shall be construed as providing consult or advice to you.



General Conditions


We reserve the right to refuse service to anyone for any reason at any time



Intellectual Property Rights


The intellectual property rights in all software and content (including photographic images) made available to you on or through the Website remains the property of FHP or its licensors and are protected by copyright laws and treaties around the world. All such rights are reserved by FHL and its licensors. You may store, print and display the content supplied solely for your own personal use. You are not permitted to publish, manipulate, distribute or otherwise reproduce, in any format, any of the content or copies of the content supplied to you or which appears on the Website nor may you use any such content in connection with any business or commercial enterprise.



Disclaimer of Liability


In no event shall FHP, nor any of its officers, directors and employees, be liable to you for anything arising out of or in any way connected with your use of the Website, whether such liability is under contract, tort or otherwise, and FHP including its officers, directors and employees shall not be liable for any indirect, consequential or special liability arising out of or in any way related to your use of the Website.



Indemnity


You agree to indemnify, defend and hold harmless FHP, its directors, officers, employees, consultants, agents, and affiliates, from and against any and all liabilities, costs, demands, causes of action, damages and expenses (including reasonable attorney’s fees) arising out of or in any way related to your breach of any of the provisions of the Terms.



Variation


FHP shall have the right in its absolute discretion at any time and without notice to amend, remove or vary the Website and/or any page of the Website. You should check this page regularly to take notice of any changes we may have made to the Terms.



Invalidity


If any provision of the Terms is found to be unenforceable or invalid under any applicable law, such unenforceability or invalidity shall not render the Terms unenforceable or invalid as a whole, and such provisions shall be deleted without affecting the remaining provisions herein.



Complaints


We operate a complaint handling procedure which we will use to try to resolve disputes when they first arise, please let us know if you have any complaints or comments through +852 2155 0487 or info@foresthillslab.com.



Waiver


If you breach these conditions and we take no action, we will still be entitled to use our rights and remedies in any other situation where you breach the Terms.



Entire Agreement


The above terms, including any legal notices and disclaimers contained on the Website, constitute the entire agreement of the parties and supersede any and all preceding and contemporaneous agreements between you and FHP, and supersede all prior agreements and understandings with respect to the same.

Press Releases
News
FHL Announces Phase 2 Clinical Trial for Parkinson’s Drug, Korean Medical Device Company Acquisition and Saudi JV

2021.07.20

HONG KONG, CHINA, July 20, 2021 /EINPresswire.com/ -- Forest Hills Partners Hong Kong Ltd. (Forest Hills Lab or FHL) management announced today an important FDA approval for a Phase 2 clinical trial to develop a drug for Parkinson’s and the signing of strategic initiatives in Korea and Saudi Arabia as management looks to accelerate global expansion in second half 2021.

Forest Hills Lab received US FDA approval in June to proceed with its Phase 2 clinical trial for Parkinson’s disease based on FHL’s recent Investigational New Drug (IND) filing. This clinical trial relates to one of FHL’s five drug candidates focused on central nervous system (CNS) diseases ranging from cognitive impairment disorders, such as Alzheimer’s, and movement disorders, including Parkinson’s.

FHL-301 is a repurposed peroxisome proliferator-activated receptor (PPAR)-alpha agonist drug which has shown excellent animal proof of concept to slow down or reverse the progression of Parkinson’s disease. The upcoming Phase 2 clinical trial will enroll early stage patients diagnosed with Parkinson’s in a double-blind, placebo-controlled and randomized study for a period of 52 weeks.

“We are very excited and pleased with the FDA approval to proceed with this Phase 2 clinical trial for this neurodegenerative disease,” states Alex K. Yang, Chairman of Forest Hills Lab. “This is an important milestone for a disorder that remains largely unaddressed. Currently, there is no effective drug treatment for CNS conditions that affects millions of people and the numbers are growing at an alarming rate.”

“Given our wealth of multiple drug candidates and our excellent science backgrounds, FHL is committed to launch a number of Phase 2 clinical trials for these devastating CNS disorders,” points out Dr. Hahn-Jun Lee, a member of the Science Advisory Board at Forest Hills Lab. “Our Phase 2 initiative will target appropriate patient groups in a strategically aligned manner for the clinical trial planning work ahead.”

Korean and Saudi Deals Close
Forest Hills Lab successfully closed a long-standing transaction to acquire a controlling stake of Newmedic Corp. (Newmedic), a Korean manufacturer engaged in medical devices, such as injectable dermal fillers. Newmedic, now a Korean subsidiary of FHL, recently received approval for the European CE certification on one of its HA dermal fillers and has developed a range of other promising products, such as PN fillers and meso serums, to be marketed and sold to countries worldwide.

The Newmedic acquisition is part of FHL’s stated corporate strategy to seek partners in key jurisdictions for distribution and manufacturing opportunities in the aesthetic medical device and cosmeceutical areas. Similar initiatives to the Korea transaction are being evaluated in China, the Middle East, Europe and South America.

“This acquisition of a highly reputable Korean aesthetic medical device and cosmeceutical maker is a key cornerstone for building collaborative networks with regional distributors,” states David Han, the CEO of Forest Hills Lab. “The acquisition provides FHL with a window of opportunity in the formation of strategic partnerships to develop, manufacture and market products and services in core global markets.”

In a similar initiative, FHL recently executed a collaboration agreement with Bait al Batterjee Medical Co. (Bait al Batterjee), the holding company of Saudi German Hospital Group, one of the largest private hospital and healthcare services providers in the Middle East. The new joint venture develops, manufactures and markets aesthetic medical devices, such as injectable dermal fillers, and establishes the first local manufacturing facility backed by top quality Korean medical technologies in the Middle East region.

Forest Hills Lab contributes its technical capabilities in design and manufacture of aesthetic medical devices and will inject capital to the Saudi joint venture with Bait al Batterjee. “This collaboration with a Korean company in the pharma space is a precedent for things to come,” comments Dr. Makarem Batterjee, Chairman of Bait al Batterjee. “We are most pleased and proud to form a joint venture that allows us to move forward into the medical aesthetics device market with a Saudi product based on deep Korean roots.”

About Forest Hills Lab
Forest Hills Lab is incorporated in Hong Kong with a corporate mission to deliver products and services for healthy living to the young and elderly. The cosmeceutical and medical device business focuses on HA dermal fillers and related cosmeceuticals designed and made in Korea. FHL’s HA dermal fillers are considered to be of the highest quality and are recommended by clinicians and doctors. FHL manufactures and markets these products worldwide with a footprint that is expanding in core regions through local partnerships. FHL also develops new chemical entities and repurposed drugs as disease-modifying treatment for CNS diseases, including Parkinson's, Alzheimer's, Dementia with lewy bodies. FHL plans Phase 2 clinical trials for several drug compounds with an initial focus on Parkinson's.

Forward-looking Statement
Certain information set forth in this presentation contains "forward-looking information", including but not limited to (i) the expected development of the Company's business, projects, and joint ventures; (ii) execution of the Company's vision and growth strategy, including with respect to future M&A activity and global growth; and (iii) sources and availability of third-party financing for the Company's projects. Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.

Although forward-looking statements contained in this presentation are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements. 

List